CompletedPhase 1NCT03638167
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seattle Children's Hospital
- Principal Investigator
- Juliane Gust, MD, PhDSeattle Children's Hospital
- Intervention
- EGFR806-specific chimeric antigen receptor (CAR) T cell(biological)
- Enrollment
- 11 enrolled
- Eligibility
- 1-26 years · All sexes
- Timeline
- 2019 – 2023
Study locations (1)
- Seattle Children's Hospital, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03638167 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University